Rhythm Biosciences (ASX:RHY) made a sale of its geneType cancer risk assessment test in Manila, Philippines, the first sale in Southeast Asia, according to a Thursday Australian bourse filing.
The firm partnered with Digistain in the region earlier in March. The Digistain team effectively completed the initial commercial pilot and will now scale sales across the Philippines before setting up pilots in other Southeast Asian markets.